Incyte (INCY) Q1 FY26 earnings call

Incyte delivered a strong first quarter, marked by robust sales growth across its commercial portfolio and significant advancements in its late-stage pipeline. The company is strategically transitioning beyond its cornerstone product, Jakafi, towards a diversified portfolio in hematology, oncology, and immunology. Key regulatory and clinical milestones were achieved, including the FDA acceptance of povorcitinib's NDA for HS and positive Phase III data for povorcitinib in nonsegmental vitiligo, positioning Incyte for multiple potential launches and continued long-term growth.